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Abstract
The main aim of this work was to evaluate the effect of doxorubicin in complex with C60 fullerene (C60 + Dox) on
the growth and metastasis of Lewis lung carcinoma in mice and to perform a primary screening of the potential
mechanisms of C60 + Dox complex action. We found that volume of tumor from mice treated with the C60 + Dox
complex was 1.4 times less than that in control untreated animals. The number of metastatic foci in lungs of
animals treated with C60 + Dox complex was two times less than that in control untreated animals. Western blot
analysis of tumor lysates revealed a significant decrease in the level of heat-shock protein 70 in animals treated
with C60 + Dox complex. Moreover, the treatment of tumor-bearing mice was accompanied by the increase of
cytotoxic activity of immune cells. Thus, the potential mechanisms of antitumor effect of C60 + Dox complex include
both its direct action on tumor cells by inducing cell death and increasing of stress sensitivity and an
immunomodulating effect. The obtained results provide a scientific basis for further application of C60 + Dox
nanocomplexes as treatment agents in cancer chemotherapy.
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Background
Suppression of proliferative activity of tumor cells is a
basic strategy when using traditional chemotherapeutic
drugs [1]. Doxorubicin (Dox) is the anthracycline anti-
biotic widely used for treatment of cancers of different
origin [2]. It uses two main mechanisms in cytotoxic ac-
tion towards tumor cells: intercalation into DNA helixes
followed by inhibition of the DNA synthesis and gener-
ation of free radicals followed by DNA impairment and
cell membrane damage [3]. However, the antitumor ef-
fect of traditional chemotherapy is always associated
with numerous negative side effects, in particular, the
toxicity towards cells of normal organs and tissues. Dox
causes potent oxidative stress, mitochondrial dysfunc-
tion, and Bcl-2 expression disturbance followed by the
apoptotic damage in heart tissue. A number of sub-
stances with ability to attenuate the Dox-induced cardio-
toxicity have been developed nowadays in order to
improve the outcome of the long-term treatment with
Dox [4]. In that regard, C60 fullerene is a promising car-
bon nanostructure that is characterized by unique phys-
ical and chemical properties [5] and biological activity
both in vitro and in vivo [6].
It was established that pristine C60 fullerenes at low
concentrations are nontoxic [7, 8] and they are able to
penetrate through the cytoplasmic membrane of treated
cells [9]. One of the biologically most relevant features
of C60 fullerene is its antioxidant effect [10]. Our previ-
ous results also revealed antioxidant properties of pris-
tine C60 fullerene [11].
C60 fullerene and its derivatives possess potent antican-
cer activity [12]. It has been reported that C60 fullerene
nanocrystal induces certain hallmarks of autophagy in
cancer cells [13]. The tumor inhibitory effect of fullerenes
is accompanied by the immunomodulatory activity [14].
It is important to emphasize that chemical modifica-
tion of the surface of C60 molecule for improvement of
its water solubility often leads to changes in its physical
and chemical properties and to a decrease in specific
biological effects. Thus, utilization of pristine C60 fuller-
ene would be more desirable. In our previous study [15],
we showed that the water-soluble pristine C60 fullerene
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directly suppresses growth of transplanted malignant
tumor. Chen et al. [16] reported that antitumor effect of
pristine and functionalized C60 fullerene might be asso-
ciated with modulation of the oxidative stress and the
anti-angiogenic and immunostimulatory activity. Injac et
al. [17] demonstrated the ability of fullerenol to decrease
the acute Dox pulmotoxicity in rats with malignant neo-
plasm through inhibition of oxidative stress. In our pre-
vious study [18], it was shown that the combination of
Dox with C60 fullerene resulted in increase of thera-
peutic efficacy of the treatment. Taking into account
these data, we also suggested [19, 20] that Dox
immobilization on C60 fullerene (C60 + Dox complex for-
mation) can reduce negative side effects of this drug to-
wards normal cells as well as enhance its ability to enter
target tumor cells.
The main goal of this work was to (1) evaluate the ef-
fect of C60 + Dox complex on growth and metastasis of
Lewis lung carcinoma (LLC) and (2) perform primary
screening of the potential mechanisms of C60 + Dox
action.
Methods
Material Preparation and Characterization
The highly stable aqueous colloid solution of purified
C60 fullerene (C60FAS; concentration 0.15 mg/ml) was
prepared as reviewed in [21, 22]. The method is based
on the technology of transferring C60 molecules from
toluene to an aqueous phase with the help of ultrasonic
treatment.
The atomic force microscopy (AFM) data [21–23]
confirm randomly arranged individual C60 molecules
with a diameter of ~0.7 nm and their bulk sphere-like
aggregates with a height of 2–100 nm in C60FAS.
Dox (“Doxorubicin-TEVA”, Pharmachemie B.V.) was
dissolved in saline at initial concentration 0.15 mg/ml
and used in all experiments. It was immobilized on the
С60 fullerene according to the following protocol:
C60FAS (0.15 mg/ml) and Dox (0.15 mg/ml) were mixed
in 1:2 volume ratio, and the resulting mixture was
treated for 20 min in the ultrasonic disperser. After
that, it was subjected to 12-h magnetic stirring at
room temperature. Pronounced hypochromic effect
observed in spectrophotometric experiment and AFM
data clearly indicate a formation of stable C60 + Dox
complex [19, 20].
Animals
The male С57Bl/6 mice (20–21 g weight) were kept at
298 ± 1 K on a standard diet in the vivarium of R.E.
Kavetsky Institute of Experimental Pathology, Oncology
and Radiobiology, NAS of Ukraine (Kyiv). All experi-
ments were conducted in accordance with the inter-
national principles of the European Convention for
protection of vertebrate animals under the control of
Bio-Ethics Committee of that institution.
Tumor Model, Treatment Regimens, and Study Design
LLC was used as an experimental model. LLC cell line
was obtained from the cell line bank of the R.E. Kavetsky
Institute of Experimental Pathology, Oncology and
Radiobiology, NAS of Ukraine (Kyiv). Tumor cells
(5 × 105 in the volume of 100 μl) were transplanted
intramuscularly into the mouse limb. After transplant-
ation of tumor cells, the experimental animals were
randomized by weight and distributed in four groups
with ten animals per group:
Group 1 (C60 fullerene injection). C60FAS was used in
1.5 mg/kg dose (0.2 ml) injected intraperitoneally to
mice with transplanted tumor once per day for 5 days
with a day interval [15].
Group 2 (Dox injection). Dox was used in 1.5-mg/kg
dose (0.2 ml) injected intraperitoneally to mice with
transplanted tumor once per day for 5 days with a day
interval [24].
Group 3 (C60 + Dox complex injection). C60 + Dox
mixture was used in 1.5-mg/kg dose (0.2 ml) injected
intraperitoneally to mice with transplanted tumor once
per day for 5 days with a day interval.
Control. The mice with transplanted tumor were
injected with saline (0.2 ml) once per day for 5 days
with a day interval.
Intact animals were used in order to investigate im-
munological indices (cytotoxic activity of the peritoneal
macrophages and mononuclear splenic leucocytes).
The injections of C60 fullerene, Dox, or C60 + Dox
complex were started on the 2nd day after tumor cell
transplantation. The protocol of injecting C60 fullerenes
was based on the fact that C60 fullerenes administered
intraperitoneally to rats (500 mg/kg) were subjected to
clearance from the organism within 2–4 days [25]. The
C60 fullerene dose applied in our experiments was sig-
nificantly lower than the LD50 value determined for C60
fullerene which, after oral administration to mice, was
equivalent to 600 mg/kg of body weight [25].
The kinetics of tumor growth was evaluated as de-
scribed [15] by linear dimensions of tumor measured
every third day with the use of calipers starting from the
9th day after tumor cell inoculation. The euthanasia of
experimental animals was performed at the end of the
experiment (22nd day), and the number and size of me-
tastases in animal lungs were monitored.
Anticancer effect was also characterized by growth
inhibition index, GII, calculated by the formula
GII = (Vc ‐Vexp)/Vc × 100 %, where Vc and Vexp are the
average volumes of tumor of control and experimental
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animals, respectively; V ¼ 1=2⋅ aþb2
 3
, where а and b are
the length and width (in millimeters) of the tumor site, re-
spectively [15].
MTT Assay
To analyze cytotoxic activity of the peritoneal macro-
phages and mononuclear splenic leukocytes, the modi-
fied MTT assay was used as described [26]. Cytotoxic
activity of the studied samples was calculated using the
formula Cytotoxicity index = (1–ε/εc) × 100 %, where εc
and ε are the extinctions of control and test sample, re-
spectively. Measurement of extinction was performed on
a digital spectrophotometer (μQuant, BioTEK, USA) at
the wavelength of 540 nm.
The investigation of cytotoxic activity of immunocytes
was performed on the 22nd day after tumor cell trans-
plantation. Suspension of tumor cells was prepared from
tissue homogenates. Mononuclear splenic leukocytes
were obtained from splenocyte suspension by centrifuga-
tion (1500 rpm, 40 min) in Ficoll-Hypaque density gradi-
ent (p = 1.077). Peritoneal macrophages were isolated
without preliminary stimulation. Mice were sacrificed, and
peritoneal macrophages were harvested using phosphate-
buffered saline containing 100 U/ml of heparin. Cells were
centrifuged at 300×g for 5 min at 4 °C, washed twice with
serum-free DMEM, and re-suspended in DMEM contain-
ing 10 % FCS and 40 μg/ml gentamicin.
To perform cytotoxic assay, LLC cells were placed in 96-
well plates (3 × 105 cells/well), and mononuclear splenic
leukocytes or peritoneal macrophages were added at 20:1
ratio. Cells were incubated in a RPMI-1640 medium
supplemented with gentamicin sulfate (100 μg/ml) and
maintained at 37 °C for 18 h in 5 % CO2 atmosphere. After
incubation, MTT (Sigma) was added to a final
concentration of 0.5 mg/ml followed by culturing for 3 h.
After culturing, cells were centrifuged at 4000 rpm
(1600×g) for 10 min. Culture medium was removed, and
blue formazan crystals were dissolved in 100 μl DMSO.
Optical density was determined at 570 nm.
Western Blot Analysis
The tumors were surgically removed, and cell lysates
were prepared by EDTA extraction. After removal of
unlysed cell remnants and nuclei by centrifugation in
the Eppendorf micro-centrifuge (5 min, 10,000 rpm,
10,200×g); protein concentration was determined by
standard method, as described [27]; and 10 μg of equal
amounts of protein was loaded into 15 % polyacrylamide
gel. Proteins were resolved and transferred to Immobilon-
P membrane (Millipore, Billerica, MA) using semi-dry
transfer (Bio-Rad, Hercules, CA). After incubating the
membrane in the blocking buffer, the membrane was in-
cubated with heat-shock protein 70 (HSP70) monoclonal
antibodies (Santa Cruz Biotechnology, Santa Cruz, CA).
For a loading control, the levels of expression of the β-
actin were detected in each sample using mouse β-actin
monoclonal antibodies (Sigma). Immunoreactive bands
were visualized by chemiluminescence using horseradish
Fig. 1 The effect of treatment with C60 fullerene, Dox, and C60 + Dox complex on tumor volume in LLC-bearing mice; the differences are statistically
valid compared to the control (t test; *p < 0.05, **p < 0.01)
Table 1 Tumor growth inhibition index (GII, %) for each
experimental group on the 9th, 13th, 18th, and 22nd day after
tumor inoculation
Animal group Day after tumor cell
transplantation
9 13 18 22
Group 1 (C60 fullerene injection), n= 10 26 20 22 12
Group 2 (Dox injection), n = 10 13 22 21 13
Group 3 (C60 + Dox injection), n = 10 24 22 29 29
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peroxidase-conjugated IgG antibodies and ECL Kit
(Amersham, Uppsala, Sweden) according to the instruc-
tions of the manufacturer.
Statistical Analysis
For statistical analysis of the obtained results, standard
variation data within a group was calculated together
with a statistical reliability of differences between two
groups of data assessed by Student’s t test. The level of
significance was set to p < 0.05.
Results and Discussion
Treatment with C60 + Dox Complex Results in the
Inhibition of Tumor Growth and Metastasis and Increases
Stress Sensitivity of Tumor Cells In Vivo
Experimental animals tolerated the treatment well and
exhibited normal behavior, as determined by the activity
level and grooming behavior throughout the study.
LLC was characterized by a significant growth of its size
(volume) from the 9th to the 22nd day of the experiment
(Fig. 1). One can see that all applied treatments (C60 ful-
lerene, Dox, and C60 + Dox complex) caused a decrease
(comparing to control, i.e., untreated mice) of tumor vol-
ume. Tumor volume in animals of group 1 (C60 fullerene
injection) and group 2 (Dox injection) differed slightly.
The volume of tumor from mice treated with the C60 +
Dox complex was significantly lower than that in control
untreated animals, viz. by 1.4 times.
The effect of C60 fullerene and Dox used alone and in
C60 + Dox complex on tumor growth was evaluated by
the GII value presented in Table 1.
Thus, on the 13th day after cancer cell inoculation,
tumor volume in mice treated with Dox and C60 + Dox
complex was 22 % less than that in the untreated ani-
mals. There was no inhibition of tumor growth in mice
treated with C60 fullerene alone. On the 18th day after
cancer cell transplantation, we observed the most
expressed retardation of tumor growth in animals treated
with C60 + Dox complex, and the GII value in mice of that
group was 29 %. At that time point, the tumor volume in
mice treated with C60 fullerene and Dox was ~22 % less
than that in the untreated animals. On the 22nd day after
cancer cell inoculation, the GII value in mice treated with
C60 fullerene and Dox was decreased by ~13 %, but it did
not change in mice treated with C60 + Dox complex.
The treatment of tumor-bearing mice with C60 fuller-
ene, Dox, and C60 + Dox complex caused an inhibition
of metastasis of the experimental tumor (Table 2). The
number of the metastatic foci in lungs of animals of the
group treated with C60 + Dox complex was two times
less than that in the untreated animals and 1.4 times less
than that in mice treated with Dox alone. It should be
noted that the metastatic foci in mice treated with C60
fullerene, Dox, and its complex were characterized by
different sizes. While in the control group, large meta-
static foci that infiltrated into the lung parenchyma were
observed; the metastatic foci were much smaller and
solitary in mice treated with Dox and C60 + Dox com-
plex. In mice treated with C60 + Dox complex, the meta-
static foci with the diameter of ≥3 mm were absent.
Since only tumor growth beyond the size of 1–2 mm
is angiogenesis-dependent [28], we suggested that the
small-sized metastatic focus (≤1 mm in diameter) is
in a state of dormancy. Therefore, one can suppose
that C60 + Dox complex exerts a negative effect to-
wards tumor angiogenesis.
Table 2 The effect of C60 fullerene and Dox used alone and in C60 + Dox complex on the LLC metastases
Animal group The number of tumor nodules in lungs
Nodule diameter (mm) Total
number<0.5 0.5 1 2 3 4 5
Control, n = 10 12 9 33 25 3 7 11 100
Group 1(C60 fullerene injection), n = 10 20 22 23 8 9 1 1 84
Group 2(Dox injection), n = 10 14 5 25 16 7 1 1 69
Group 3(C60 + Dox injection), n = 10 16 10 6 16 – – – 48
Fig. 2 The effect of treatment with C60 + Dox complex on the level of HSP70 in tumor tissue of animals with LLC (representative Western blot).
1 and 2—control animals (untreated); 3 and 4—C60 + Dox-treated animals
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It is known that HSP70 is aberrantly expressed in
cancer cells of different origins. The survival of these
cells strongly depends upon HSPs due to their role not
only in protein refolding and degradation but also in
preventing apoptosis [29]. Elevated expression of
HSP70 is associated with poor response of tumor cells
to chemotherapy, and inhibition of its expression was
shown to be an effective strategy against cancer [30].
Therefore, we have measured the level of HSP70 in
tumor tissue of animals treated with Dox and C60 +
Dox complex. Western blot analysis of tumor cell ly-
sates revealed a significant decrease in HSP70 level only
in animals treated with C60 + Dox complex (Fig. 2). The
level of HSP70 in tumor lysates from mice treated with
Dox alone did not differ from that in the untreated
tumor-bearing mice.
The obtained results clearly demonstrate that the anti-
cancer activity of Dox is not only well preserved in its
complex with C60 fullerene, but it is even enhanced after
formation of such complex.
C60 + Dox Complex Modulates Immunological Reactivity
of Tumor-Bearing Mice
С60 fullerene and its derivatives were shown to possess
the immunomodulating properties [14]. Thus, we sup-
posed that the immunomodulating effect of С60 + Dox
complex can be involved in its antitumor action. To test-
ify this hypothesis, the cytotoxic activity of mononuclear
splenic leukocytes and macrophages towards autologic
tumor cells was evaluated in tumor-bearing mice treated
with the С60 + Dox complex.
Fig. 3 The effect of treatment with C60 fullerene, Dox, and C60 + Dox complex on the cytotoxic activity of peritoneal macrophages towards
autologic tumor cells in LLC-bearing mice; *the differences are statistically valid compared to the control (t test; p < 0.05); **the differences are
statistically valid compared to the intact animals (t test; p < 0.05)
Fig. 4 The effect of treatment with C60 fullerene, Dox, and C60 + Dox complex on the cytotoxic activity of mononuclear splenic leukocytes
towards autologic tumor cells in LLC-bearing mice; *the differences are statistically valid compared to the control and intact animals
(t test; p < 0.05)
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Growth of experimental tumor was associated with a
decrease of macrophage cytotoxicity towards autologic
tumor cells in vitro (Fig. 3).
Treatment with Dox as well as with С60 fullerene used
alone and in С60 + Dox complex resulted in increased
cytotoxic activity of the peritoneal macrophages of
tumor-bearing mice. Cytotoxic indices of the peritoneal
phagocytes in treated animals were comparable with
those in the intact mice.
Cytotoxic activity of splenic mononuclear leukocytes
in tumor-bearing mice did not differ from that in the in-
tact animals (Fig. 4).
Treatment with Dox resulted in an increase of spleno-
cyte cytotoxicity. A significant individual variability of
cytotoxic indices in animals from this group should be
noted. Cytotoxicity indices of the mononuclear splenic
leukocytes in animals treated with С60 fullerene used
alone and in С60 + Dox complex were significantly
higher than those in the untreated tumor-bearing mice.
The most positive effect was observed in animals receiv-
ing С60 + Dox complex. Cytotoxic activity of splenic
mononuclear cells towards autologic tumor cells is sub-
stantially mediated by splenic NK cells [31]. Turabekova
M et al. reported that С60 fullerene might be recognized
by Toll-like receptors (TLRs) [32]. TLR-dependent
stimulatory effect of the preparation and an increased
stress sensitivity of LLC cells associated with a decreased
HSP70 expression might be potential reasons of in-
creased cytotoxicity of splenic mononuclear cells in ani-
mals receiving С60 + Dox complex.
Conclusions
The results of performed experiments demonstrated that
treatment of mice bearing LLC with C60 + Dox nano-
complexes is associated with a significant antitumor effect,
namely, (1) the volume of tumor of mice treated with C60
+ Dox complex was 1.4 times smaller than that in the con-
trol untreated animals; (2) the number of metastatic foci
in lungs of animals of the group treated with C60 + Dox
complex was two times smaller than that in control un-
treated animals; (3) there were no metastatic foci with
diameter ≥3 mm in mice treated with C60 + Dox complex.
Western blot analysis of tumor cell lysates of animals
treated with C60 + Dox complex revealed a significant de-
crease in the HSP70 level. The MTT assay showed that
C60 + Dox complex modulates immunological reactivity of
tumor-bearing mice. The potential mechanisms of C60 +
Dox complex antitumor effect are likely to be based on its
direct action on tumor cells with inducing cell death as
well as an increasing of stress sensitivity and immunomo-
dulating effect. Thus, the C60 + Dox nanocomplexes might
be proposed as new pharmacological agents that are ef-
fectively killing tumor cells and simultaneously stimulat-
ing immune responses in tumor-bearing mice.
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